Madrigal Pharmaceuticals (MDGL) Shares Outstanding (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 16 years of Shares Outstanding (Entity) data on file, last reported at $29.0 million in Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 30.85% year-over-year to $29.0 million in Q1 2026; TTM through Mar 2026 was $29.0 million, a 30.85% increase from a year earlier, with the FY2025 full-year figure at $22.8 million, up 3.81% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $29.0 million, up from $22.8 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for MDGL reached as high as $29.0 million in Q1 2026 and fell as low as $17.1 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $20.4 million across 5 years, with a median of $19.9 million in 2023.
• Across the five-year window, Shares Outstanding (Entity) grew 1.44% in 2022 and soared 30.85% in 2026, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $18.1 million in 2022, then advanced by 9.79% to $19.9 million in 2023, then climbed by 10.71% to $22.0 million in 2024, then gained by 3.81% to $22.8 million in 2025, then gained by 27.1% to $29.0 million in 2026.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $29.0 million in Q1 2026, $22.8 million in Q4 2025, and $22.7 million in Q3 2025.